imageEuropean ME Alliance

The members of the European ME Alliance have put forward a petition to the European Parliament in Brussels. EMEA feel there is an urgent requirement to address the perception, treatment and research into myalgic encephalomyelitis.


Letters have been sent to all of the Alliance's members of the European Parliament -


Dear Members of the European Parliament,


The European ME Alliance (EMEA) is a grouping of European organisations that are involved in supporting patients suffering from myalgic encephalomyelitis (ME) - (in some countries ME is embraced in the term ME/CFS or even CFS) and the Alliance campaigns for a strategy of biomedical research into ME in order to provide treatments and cures for this neurological disease.


The Alliance consists of member organisations from Belgium, Germany, Holland, Ireland, Italy, Norway, Spain, Sweden, Switzerland, Denmark and UK.


The representatives of the European ME Alliance wish to ask for your support of the attached petition.

The petition seeks to ensure that member states of the EU abide by, enforce and respect the following: -

  • that myalgic encephalomyelitis is treated as a neurological disease

  • the medical and civil rights of people suffering from ME are respected

  • the most recent criteria for diagnosis of ME are used by member states

  • biomedical research on ME is fostered and funded by the EU

  • discrimination against people with ME is stopped

EMEA Belgium will represent the Alliance in any discussions with the EU that are held in Brussels.


We hope we can count on your support for this petition.


Yours Sincerely,


The Chairman, Board and Members of the European ME Alliance


European ME Alliance



ME/CFS Association

Denmark Dansk ME Forening
Ireland    Irish ME Trust

Associazione Malati di CFS

Germany Fatigatio e.V.
Netherlands Het Alternatief
Norway  Norges M.E. Forening
Spain Liga SFC
Sweden   Riksföreningen för ME-patienter
Switzerland   Verein CFS Schweiz

Invest in ME







The legal and medical situation of ME (Myalgic Encephalomyelitis) and CFS (Chronic Fatigue Syndrome) patients


Myalgic  Encephalomyelitis (ME) was accepted by the WHO as a neurological disease in 1969.

In some countries ME is referred to as Chronic Fatigue Syndrome (CFS). In 1993 CFS was added as an addendum to ICD-10 but the “fatigue”-based definition of CFS still causes confusion and problems for patients, as was stated by Mrs. Androulla Vassiliou, former European Health Commissioner.


ME can occur in outbreaks: one was described for the first time in 1934.

Experts have placed ME in the same category as cancer and late stage AIDS regarding quality of life and suffering.


We therefore request the following:

  • to respect the WHO ICD-10-Code G93.3 for ME as a neurological disease and ensure that the Member States implement this in their Health Care System;

  • to respect the rights of ME patients – including children - in all Member States;
  • to endorse as diagnostic criteria for ME the Canadian Consensus Criteria and the developing International Consensus Criteria;
  • to encourage the development of biomedical research.


An estimated 1.200.000 very sick ME patients in Europe are waiting for parliament to recognise the WHO ICD-10-Code G93.3.





G93.3      Postviral fatigue syndrome

                           Benign myalgic encephalomyelitis (ME)

2.   Carruthers B, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles AP, et al.: Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. Journal of chronic fatigue syndrome 2003, 11(1):7-115.


3.   Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011;270:327–38.


4.   Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler MD, Leite JC, Poland F, Howe A, Fayyaz S, Molokhia M: The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. BMC Public Health 2011, 11(1):402.


5.   J. Mark Van Ness, Staci R. Stevens, Kylie T. Kumasaka, Harnoor Singh, Betsy Keller, Daniel L. Peterson, Jose Montoya and Christopher R. Snell:  A diagnostic test for the identification of metabolic dysfunction. Conference abstract 9th IACFS/ME clinical and research conference, Reno, March 7, 2009.


6.   Brown, M. M., Bell, D. S., Jason, L. A., Christos, C. and Bell, D. E. (2012), Understanding Long-Term Outcomes of Chronic Fatigue Syndrome. J. Clin. Psychol., 68: 1028–1035. doi: 10.1002/jclp.21880


7.   Twisk, F.N., Maes, M., 2009. A review on cognitive behavioral therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/ chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinology Letters 30 (3), 284–299.


8.   KCE report: Evaluation of CBT/GET therapy.


9.   Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, et al. (2011) Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. PLoS ONE 6(10): e26358. doi:10.1371/journal.pone.0026358


10. Maes M, Twisk FN: Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 8:35.


11. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010 Oct;24(7):1209-17. 


12. Komaroff AL, Cho TA: Role of infection and neurologic dysfunction in chronic fatigue syndrome. Seminars in Neurology 2011, in press.



For further information

1.   Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403-10. [PMID: 2166084]

2.   Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009; 2: 1-16. [PMID: 19436827]

3.   Peckerman, A., LaManca, J.J., Dahl, K.A., Chemitiganti, R., Qureishi, B., Natelson, B.H., 2003. Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. American Journal of Medical Sciences 326 (2), 55–60.

4.   Streeten DH, Thomas D, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med 2000; 320: 1-8. [PMID: 10910366]

5.   Kerr JR, Burke B, Petty R, et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis; a detailed analysis of gene network and clinical phenotypes. J Clin Pathol 2008; 61: 730-739. [PMID: 18057078]

6.   Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, Ferlin G. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Amer J Med 1998; 105: 54S-8S. [PMID: 9790483]

7.   Goldstein JA. Chronic Fatigue Syndrome: The Limbic Hypothesis. Binghamptom, New York: Haworth Medical Press; 1993:19, 116.

8.   Chia J, Chia A, Voeller M, Lee T, Chang R. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome and viral persistence. J Clin Pathol 2010; 63: 163-8. [PMID: 19828908]

9.   Pall ML. Explaining “Unexplained Illnesses”: Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others. Bighamton, NY: Harrington Park (Haworth) Press, 2007.

10. Meeus M, Nijs J, McGregor N, Meeusen R, De Schutter G, Truijen S, Frémont M, Van Hoof E, De Meirleir K.: Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. In Vivo. 2008 Jan-Feb;22(1):115-21.PMID:18396793 [PubMed - indexed for MEDLINE]


For an objective view of the establishment intrigue surrounding ME we recommend:  


Magical Medicine: How to Make a Disease Disappear by Professor Malcolm Hooper [click here]


Professor Hooper has made a formal complaint to the Minister of State responsible for the Medical Research Council.



See the petition document in other languages

Coming shortly
Coming shortly
Coming shortly
Coming shortly
coming soon



Last Update: 22 October 2012

Return to News

Membership into EMEA is open to all groups

Contact us if you are interested in influencing ME in Europe and beyond.